Literature DB >> 10085443

Biochemical parameters, nutritional status and efficiency of dialysis in CAPD and CCPD patients.

H Gao1, S Q Lew, J P Bosch.   

Abstract

BACKGROUND/AIMS: Several studies indicate that small solute transport is influenced by peritoneal dialysate volume and dwell time. This study focuses on the clinical impact of peritoneal dialysis modality, continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD).
METHODS: We studied 18 patients on CAPD and 11 on CCPD for 18 months and assessed biochemical parameters, nutritional status and efficiency of dialysis at 6-month intervals.
RESULTS: Four-hour D/P urea and creatinine ratios were similar in both CAPD and CCPD patients. However, 24-hour D/P urea and creatinine ratios were significantly higher in CAPD than in CCPD patients (0.9 +/- 0.1 vs. 0.8 +/- 0.2 and 0.8 +/- 0.1 vs. 0.6 +/- 0.2, p < 0.05 and p < 0.01, respectively). The dialysate urea nitrogen concentration was significantly different between the two groups (65 +/- 14 mg/dl in CAPD, 48 +/- 13 mg/dl in CCPD; p < 0.05). Total weekly Kt/V and total weekly creatinine clearance were not significantly different between CAPD and CCPD patients at 18 months (1.6 +/- 0.4 vs. 1.7 +/- 0.3 and 52 +/- 21 vs. 50 +/- 12 liters, respectively). Two-way ANOVA with a post-hoc Bonferroni-Dunn test showed serum potassium concentration was significantly lower in CCPD patients at 18 months (3.8 +/- 0.5 mEq/l, p < 0.05), and significant increases in triglyceride levels in the CAPD groups by 18 months (301 +/- 286 mg/dl, p < 0.05).
CONCLUSION: This study demonstrates that the mean serum triglyceride level increases in CAPD patients over time, and the mean serum potassium concentration decreases in CCPD patients at 18 months. Dialysis adequacy and nutritional status are not significantly different between the two peritoneal dialysis modalities, CAPD and CCPD. We suggest the peritoneal dialysis prescription for CAPD or CCPD with respect to volume and frequency of exchanges be individualized to achieve adequate of therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085443     DOI: 10.1159/000013418

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  4 in total

Review 1.  Prevalence and pathogenesis of hypokalemia in patients on chronic peritoneal dialysis: one center's experience and review of the literature.

Authors:  Effie Tziviskou; Carlos Musso; Vincenzo Bellizzi; Mukesh Khandelwal; Tao Wang; Shokoufeh Savaj; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

Review 2.  Potassium metabolism in patients with chronic kidney disease. Part II: patients on dialysis (stage 5).

Authors:  Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

3.  Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients.

Authors:  Amit Langote; Swapnil Hiremath; Marcel Ruzicka; Brendan B McCormick
Journal:  PLoS One       Date:  2017-11-10       Impact factor: 3.240

4.  Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality.

Authors:  Qingdong Xu; Fenghua Xu; Li Fan; Liping Xiong; Huiyan Li; Shirong Cao; Xiaoyan Lin; Zhihua Zheng; Xueqing Yu; Haiping Mao
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.